Search - tctmd.com

Displaying 41 - 60 of 65

Sort: Relevancy | Date

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

Sapien 3 Valve Approved in Europe for Low-Risk Patients

Michael O'Riordan

November 06, 2019

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Daily News

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Michael O'Riordan

May 06, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Daily News

FDA Approves Lotus Edge, Ushering Third Device Into US Market

Shelley Wood

April 24, 2019

News Daily News

FDA Approves Orsiro Ultrathin-Strut Stent for CAD

Michael O'Riordan

February 22, 2019

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Daily News

FDA Approves HeartMate 3 as Destination Therapy in Advanced HF

Michael O'Riordan

October 19, 2018

News Daily News

High-Risk Medical Device Approval Process in Europe Inches Towards Transparency

Michael O'Riordan

July 20, 2018

News Daily News

Implantable Cardiac Monitor for High-Risk ACS Patients Wins FDA Approval

Michael O'Riordan

May 08, 2018

News Conference News ACC 2018

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

Michael O'Riordan

March 11, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Michael O'Riordan

July 10, 2017

News Daily News

Betrixaban Approved for Prevention of VTE

Michael O'Riordan

June 23, 2017

News Daily News

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Michael O'Riordan

June 06, 2017

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

Advertisement

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Sapien 3 Valve Approved in Europe for Low-Risk Patients

FDA Expands TAVR Indication to Low-Risk Patients

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

FDA Approves Lotus Edge, Ushering Third Device Into US Market

FDA Approves Orsiro Ultrathin-Strut Stent for CAD

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

FDA Approves HeartMate 3 as Destination Therapy in Advanced HF

High-Risk Medical Device Approval Process in Europe Inches Towards Transparency

Implantable Cardiac Monitor for High-Risk ACS Patients Wins FDA Approval

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Betrixaban Approved for Prevention of VTE

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content